Save over 60% on Fotivda from Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe ALMAC PHARMA SERVICES (IRELAND) LIMITED Finnabair Industrial Estate Dundalk Co. Louth A91 P9KD Ireland
Information about Fotivda (Tivozanib)
Fotivda is an oral medication classified as a tyrosine kinase inhibitor. It is primarily used for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior therapy.
Product Highlights
- Inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, including VEGFR, PDGFR, and c-KIT.
- Treatment of advanced renal cell carcinoma (RCC) in adults who have received prior anti-cancer therapy.
Key Ingredient
Key Benefits
- Specifically targets cancer cells while sparing normal cells, potentially leading to fewer side effects.
- May offer better progression-free survival compared to some other treatments for RCC.
- Once-daily dosing can improve patient adherence.
Direction of Use
- Take orally, with or without food.
- Follow the healthcare provider’s instructions; the typical starting dose is often 1 mg daily for a specified duration.
- Take it at the same time each day to ensure consistent levels in the bloodstream.
Safety Concerns
- Monitor blood pressure regularly, as Tivozanib can cause elevated blood pressure.
- May increase the risk of heart-related issues.
- Liver enzyme levels should be monitored; dose adjustments may be necessary for abnormal liver function.
- Possible nausea, diarrhea, or vomiting.
Avoid Fotivda (Tivozanib) If
- You have a known allergy to Tivozanib or any of its ingredients.
- You have severe liver disease or dysfunction.
- You are pregnant or planning to become pregnant without discussing risks with a healthcare provider.
- You are breastfeeding without consulting a healthcare professional.
- You have a history of certain cardiovascular conditions that may increase the risk of serious side effects.
